{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:22:38Z","timestamp":1792167758242,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SKELMET Forschergruppe-1586"],"award-info":[{"award-number":["SKELMET Forschergruppe-1586"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13058-017-0885-7","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T05:24:48Z","timestamp":1502256288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Andrew J.","family":"Browne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie L.","family":"Kubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman D.","family":"Rachner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"885_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12:215.","journal-title":"Breast Cancer Res"},{"key":"885_CR2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/bonekey.2015.60","volume":"4","author":"P Hadji","year":"2015","unstructured":"Hadji P. Cancer treatment-induced bone loss in women with breast cancer. Bonekey Rep. 2015;4:692.","journal-title":"Bonekey Rep"},{"key":"885_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2006.03.022","volume":"33","author":"A Brufsky","year":"2006","unstructured":"Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol. 2006;33:13\u20137.","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"885_CR4","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.3816\/CBC.2007.s.009","volume":"8","author":"AM Brufsky","year":"2007","unstructured":"Brufsky AM. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2007;8 Suppl 1:S22\u201334.","journal-title":"Clin Breast Cancer"},{"key":"885_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61\u20136.","journal-title":"Br J Cancer"},{"key":"885_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"885_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2016.04.006","volume":"87","author":"A Irelli","year":"2016","unstructured":"Irelli A, Cocciolone V, Cannita K, Zugaro L, Di Staso M, Lanfiuti Baldi P, et al. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone. 2016;87:169\u201375.","journal-title":"Bone"},{"key":"885_CR8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"key":"885_CR9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","volume":"18","author":"M Beeram","year":"2007","unstructured":"Beeram M, Tan QTTN, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007;18:1323\u20138.","journal-title":"Ann Oncol"},{"key":"885_CR10","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller TW, Hennessy BT, Gonz\u00e1lez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010;120:2406\u201313.","journal-title":"J Clin Invest"},{"key":"885_CR11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12885-016-2490-z","volume":"16","author":"A Lui","year":"2016","unstructured":"Lui A, New J, Ogony J, Thomas S, Lewis-Wambi J. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer. 2016;16:487.","journal-title":"BMC Cancer"},{"key":"885_CR12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139.","journal-title":"N Engl J Med"},{"key":"885_CR13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","volume":"105","author":"M Gnant","year":"2013","unstructured":"Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105:654\u201363.","journal-title":"J Natl Cancer Inst"},{"key":"885_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.critrevonc.2013.05.015","volume":"87","author":"P Hadji","year":"2013","unstructured":"Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013;87:101\u201311.","journal-title":"Crit Rev Oncol Hematol"},{"key":"885_CR15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","volume":"10","author":"H Glantschnig","year":"2003","unstructured":"Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNF\u03b1 and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase. Cell Death Differ. 2003;10:1165\u201377.","journal-title":"Cell Death Differ"},{"key":"885_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2009.04.084","volume":"384","author":"M Mogi","year":"2009","unstructured":"Mogi M, Kondo A. Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun. 2009;384:82\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"885_CR17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","volume":"35","author":"M Kneissel","year":"2004","unstructured":"Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004;35:1144\u201356.","journal-title":"Bone"},{"key":"885_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jbo.2013.05.003","volume":"2","author":"TD Rachner","year":"2013","unstructured":"Rachner TD, G\u00f6bel A, Junker M, H\u00f6tzel J, Benad-Mehner P, Hadji P, et al. Regulation of VEGF by mevalonate pathway inhibition in breast cancer. J Bone Oncol. 2013;2:110\u20135.","journal-title":"J Bone Oncol"},{"key":"885_CR19","doi-asserted-by":"crossref","first-page":"e2119","DOI":"10.1038\/cddis.2016.32","volume":"7","author":"AJ Browne","year":"2016","unstructured":"Browne AJ, G\u00f6bel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 2016;7:e2119.","journal-title":"Cell Death Dis"},{"key":"885_CR20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852\u20136.","journal-title":"N Engl J Med"},{"key":"885_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CGM.S5229","volume":"3","author":"A Politano","year":"2010","unstructured":"Politano A, Butcher M, Zeadin M, Gross P, Vaezzadeh N, Shaughnessy SG. Targeted knockdown of tissue factor in B16F10 melanoma cells suppresses their ability to metastasize to bone and cause cancellous bone loss. Cancer Growth Metastasis. 2010;3:21\u201333.","journal-title":"Cancer Growth Metastasis"},{"key":"885_CR22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bonekey.2016.31","volume":"5","author":"LE Wright","year":"2016","unstructured":"Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, et al. Murine models of breast cancer bone metastasis. Bonekey Rep. 2016;5:804.","journal-title":"Bonekey Rep"},{"key":"885_CR23","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1002\/cncr.25320","volume":"116","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma. Cancer. 2010;116:4122\u20139.","journal-title":"Cancer"},{"key":"885_CR24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e31827b45d4","volume":"37","author":"RS Dronca","year":"2014","unstructured":"Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EAT, Thompson M, et al. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma. Am J Clin Oncol. 2014;37:369\u201376.","journal-title":"Am J Clin Oncol"},{"key":"885_CR25","first-page":"31","volume":"5","author":"JG Monzon","year":"2012","unstructured":"Monzon JG, Dancey J. Targeted agents for the treatment of metastatic melanoma. Onco Targets Ther. 2012;5:31\u201346.","journal-title":"Onco Targets Ther"},{"key":"885_CR26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1078-0432.CCR-15-1110","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, et al. Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors. Clin Cancer Res. 2016;22:1018\u201327.","journal-title":"Clin Cancer Res"},{"key":"885_CR27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","volume":"103","author":"M Yunokawa","year":"2012","unstructured":"Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012;103:1665\u201371.","journal-title":"Cancer Sci"},{"key":"885_CR28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1158\/1535-7163.MCT-05-0400","volume":"5","author":"JM Albert","year":"2006","unstructured":"Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt\/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006;5:1183\u20139.","journal-title":"Mol Cancer Ther"},{"key":"885_CR29","first-page":"1627","volume":"32","author":"H Liu","year":"2012","unstructured":"Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012;32:1627\u201337.","journal-title":"Anticancer Res"},{"key":"885_CR30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2012.02.053","volume":"48","author":"X Zhang","year":"2012","unstructured":"Zhang X, Zhang S, Liu Y, Liu J, Ma Y, Zhu Y, et al. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells. Eur J Cancer. 2012;48:1581\u201392.","journal-title":"Eur J Cancer"},{"key":"885_CR31","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/jbmr.1976","volume":"28","author":"Y Indo","year":"2013","unstructured":"Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013;28:2392\u20139.","journal-title":"J Bone Miner Res"},{"key":"885_CR32","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.27504","volume":"62","author":"D Cejka","year":"2010","unstructured":"Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2294\u2013302.","journal-title":"Arthritis Rheum"},{"key":"885_CR33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00223-001-1138-3","volume":"71","author":"C Shui","year":"2002","unstructured":"Shui C, Riggs BL, Khosla S. The immunosuppressant rapamycin, alone or with transforming growth factor-\u03b2, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int. 2002;71:437\u201346.","journal-title":"Calcif Tissue Int"},{"key":"885_CR34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-15-0720","volume":"15","author":"S Mukhopadhyay","year":"2016","unstructured":"Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The enigma of rapamycin dosage. Mol Cancer Ther. 2016;15:347\u201353.","journal-title":"Mol Cancer Ther"},{"key":"885_CR35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","volume":"16","author":"PJ Houghton","year":"2010","unstructured":"Houghton PJ. Everolimus. Clin Cancer Res. 2010;16:1368\u201372.","journal-title":"Clin Cancer Res"},{"key":"885_CR36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/acel.12405","volume":"15","author":"SI Arriola Apelo","year":"2016","unstructured":"Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15:28\u201338.","journal-title":"Aging Cell"},{"key":"885_CR37","doi-asserted-by":"crossref","first-page":"E1827","DOI":"10.3390\/ijms17111827","volume":"17","author":"L Mercatali","year":"2016","unstructured":"Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, et al. The effect of everolimus in an in vitro model of triple negative breast cancer and osteoclasts. Int J Mol Sci. 2016;17:E1827.","journal-title":"Int J Mol Sci"},{"key":"885_CR38","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/stem.1931","volume":"33","author":"SK Martin","year":"2015","unstructured":"Martin SK, Fitter S, Dutta AK, Matthews MP, Walkley CR, Hall MN, et al. Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells. 2015;33:1359\u201365.","journal-title":"Stem Cells"},{"key":"885_CR39","doi-asserted-by":"crossref","first-page":"e0130627","DOI":"10.1371\/journal.pone.0130627","volume":"10","author":"J Chen","year":"2015","unstructured":"Chen J, Long F. mTORC1 signaling promotes osteoblast differentiation from preosteoblasts. PLoS One. 2015;10:e0130627.","journal-title":"PLoS One"},{"key":"885_CR40","doi-asserted-by":"crossref","first-page":"e1005426","DOI":"10.1371\/journal.pgen.1005426","volume":"11","author":"B Huang","year":"2015","unstructured":"Huang B, Wang Y, Wang W, Chen J, Lai P, Liu Z, et al. mTORC1 prevents preosteoblast differentiation through the Notch signaling pathway. PLoS Genet. 2015;11:e1005426.","journal-title":"PLoS Genet"},{"key":"885_CR41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/scd.2009.0147","volume":"19","author":"KW Lee","year":"2010","unstructured":"Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM, et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP\/Smad pathway. Stem Cells Dev. 2010;19:557\u201368.","journal-title":"Stem Cells Dev"},{"key":"885_CR42","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/jbmr.114","volume":"25","author":"SK Martin","year":"2010","unstructured":"Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, et al. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res. 2010;25:2126\u201337.","journal-title":"J Bone Miner Res"},{"key":"885_CR43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bonekey.2014.24","volume":"3","author":"M Pazianas","year":"2014","unstructured":"Pazianas M, van der Geest S, Miller P. Bisphosphonates and bone quality. Bonekey Rep. 2014;3:529.","journal-title":"Bonekey Rep"},{"key":"885_CR44","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1038\/onc.2015.414","volume":"35","author":"A Alayev","year":"2016","unstructured":"Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, et al. mTORC1 directly phosphorylates and activates ER\u03b1 upon estrogen stimulation. Oncogene. 2016;35:3535\u201343.","journal-title":"Oncogene"},{"key":"885_CR45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12885-015-1717-8","volume":"15","author":"V Simone","year":"2015","unstructured":"Simone V, Ciavarella S, Brunetti O, Savonarola A, Cives M, Tucci M, et al. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer. 2015;15:692.","journal-title":"BMC Cancer"},{"key":"885_CR46","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/abbs\/gmu069","volume":"46","author":"Y Yu","year":"2014","unstructured":"Yu Y, Song Z, Yang S, Yang X, Zhang J, Lu S. Everolimus and zoledronic acid\u2014a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta Biochim Biophys Sin. 2014;46:792\u2013801.","journal-title":"Acta Biochim Biophys Sin"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-017-0885-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T01:01:49Z","timestamp":1569978109000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-017-0885-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1186\/s13058-017-0885-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]},"article-number":"92"}}